Skye Bioscience, Inc. (SKYE)
1.80
+0.02
(+1.12%)
USD |
NASDAQ |
Sep 04, 16:00
1.80
0.00 (0.00%)
After-Hours: 16:42
Skye Bioscience Research and Development Expense (Annual) : 41.64M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 41.64M |
| December 31, 2024 | 18.70M |
| December 31, 2023 | 5.820M |
| December 31, 2022 | 5.897M |
| December 31, 2021 | 2.897M |
| December 31, 2020 | 1.942M |
| December 31, 2019 | 2.236M |
| December 31, 2018 | 0.33M |
| Date | Value |
|---|---|
| December 31, 2017 | 0.3113M |
| December 31, 2016 | 0.939M |
| December 31, 2015 | 0.5761M |
| December 31, 2014 | 0.2275M |
| October 31, 2013 | 0.00 |
| October 31, 2012 | 0.00 |
| October 31, 2011 | 0.00 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Regeneron Pharmaceuticals, Inc. | 5.306B |
| Viking Therapeutics, Inc. | 344.96M |
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |
| Anika Therapeutics, Inc. | 25.77M |